That is why we have established North-East Healthcare Investment (NEHCI), a Danish company currently working out of Switzerland, serving as the investment vehicle of North-East for direct investments in healthcare-related companies.
The investment mandate includes a broad interpretation of healthcare and covers all stages of investment from start-ups over spin-offs to mature companies.
The company facilitates investments either in collaboration with experienced executives and entrepreneurs or with other dedicated investors.
Among our healthcare investments is SNIPRBiome, a leading CRISPR and microbiome biotech company incorporated in Copenhagen, Denmark. SNIPR BIOME is engaged in the discovery and development of CRISPR/Cas-based drugs deploying its proprietary and patent-protected CRISPR/Cas platform. Specifically, SNIPR BIOME is pioneering a novel use of CRISPR/Cas technology to eradicate target bacteria selectively and precisely, while leaving the rest of the patient’s microbial community intact.
We are also invested in Exhalation Technology combating COPD through highly innovative technology. The company uses sensors to monitor respiratory conditions and inflammation through normal breathing instead of the challenging respiratory tests, which are normally used. This leads to better, more informed decisions on the right approach and, ultimately, to much better treatment.